Preliminary data in preclinical models of severe complex wounds suggests that human VSELs™ (very small embryonic like stem cells) accelerates wound healing. NeoStem hopes to advance into early clinical studies to assess therapeutic potential of VSEL technology.
NeoStem has transformed itself over the last year and half with two acquisitions, multiple financings and their expansion into China.
NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.
NeoStem announced Tuesday that Chinese generic pharma company Suzhou Erye, in which it owns a 51% majority stake, has won two awards at the 2011 Chempharm Brand Summit.
NeoStem , an international biopharmaceutical company, will present at OneMedForum NY 2011.
Though selected in order to give a platform to lesser recognized businesses, the companies presenting demonstrated the vast diversity of the healthcare and life science spaces.
NeoStem is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications.
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
Copyright © 2025 | WordPress Theme by MH Themes